The reduction in price target by HC Wainwright & Co. suggests a reassessment of Viridian Therapeutics' future financial performance or market position, potentially due to new data or market conditions. This adjustment, while maintaining a Buy rating, indicates a less optimistic but still positive view on the stock's future price performance. Investors may interpret this as a signal to adjust their expectations for the stock's growth, possibly leading to short-term price pressure.